For more information or confidential assistance
Call 800-306-3180

EMA Issues New Guidelines for Invokana

On February 12, the European Medicines Agency issued a new set of recommendations to minimize the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors — including Invokana. SGLT2 inhibitors are a type of type 2 diabetes medication designed to help lower blood sugar in... Read More

FDA Releases New Safety Communication Regarding Invokana

One of the newer generations of diabetes medications, Invokana, has come under fire in recent months for potentially increasing the risk of serious health problems. Now, the FDA has issued a new safety communication informing healthcare practitioners and patients that the agency has revised labeling information... Read More